BioSpace News Archive

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced the closing of its initial public offering of 16,560,000 shares of common stock,

Actinium Pharmaceuticals, Inc. announced that it intends to offer and sell shares of its common stock in a public offering.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Javier Rodriguez has been appointed to the company’s Board of Directors. Mr. Rodriguez is the Chief Executive Officer of DaVita Inc., a Fortune 500 company providing healthcare services to kidney disease patients throughout the United States and internationally that strives to improve patients’ quality of life through clinical innovation and integrated, personalized care

TG Therapeutics, Inc., announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present at the Raymond James 2020 Human Health Innovation Conference, being held virtually.

Apellis Pharmaceuticals, Inc. a global biopharmaceutical company pioneering targeted C3 therapies, announced that the company will present at the BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020 at 11:30 a.m. ET.

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, announced the appointment of Will Kane as Executive Vice President and Chief Commercial Officer.

eTheRNA immunotherapies NV, a clinical-stage company developing immunotherapies from its proprietary mRNA TriMix platform for the treatment of cancer and infectious diseases, announced that it has successfully raised Euro 34 million in a Series B equity financing round.

Today, Abiomed (NASDAQ: ABMD) launches a cutting-edge digital education platform called CAMP PCI , which stands for Coronary Artery & Myocardial Protected Percutaneous Coronary Intervention, to improve patient outcomes and quality of life with supported high-risk PCI by utilizing best practices, techniques and technologies to enable safer, more effective and complete revascularization. The launch of the platform, o

Vyome Therapeutics, a clinical-stage company developing locally-acting, next generation therapeutics for immuno-inflammatory diseases, today announced positive data from its Phase 2 trial of VB-1953, a first-in-class topical bactericidal and TLR-MD2 inhibitor being developed for the treatment of moderate to severe inflammatory facial acne vulgaris. Results from the trial demonstrated a statistically significant difference in the primary endp

Shockwave Medical, Inc. announced it has commenced an underwritten public offering of 1,700,000 shares of its common stock.